Renal Function
decline in renal function, chronic kidney disease
RENAL, KIDNEY
A decline in renal function (eGFR) was evident in all patients during the pre-therapy period (3 months) and was markedly more pronounced in advanced stages (Kidney function assessment (eGFR) measured over time. (A) Overall renal function. eGFR (grouped by chronic kidney disease category) per individual patient (color dots) from 3 months pre-treatment to 36 months post-treatment and the average per stage-group (solid color line), for the 4 different patient groups represented in shaded colors (3a – green; 3b – blue; 4 – orange; and 5 – red). Overall percentage improvement (+, green) or deterioration (-, red) in eGFR (renal function) by patient group at 36 months. (B) Renal function (eGFR) over 36 months for the 6 SVF treatment patients that were Stage 3b at the initiation of the study compared to untreated Stage 3b historical controls. No SVF treated patients declined in renal function, thus avoiding the need for renal dialysis (Blue field). In contrast, the untreated historical control Stage 3b group (5 patients) had a decline in renal function, requiring dialysis (eGFR <15 ML/minute) between 4-48 months (mean – 33 months) after diagnosis (Gray field). (C) Renal function (eGFR) over 36 months for the 7 SVF treatment patients that were Stage 4 at the initiation of the study compared to untreated Stage 4 historical controls. While the SVF treated patients overall demonstrated a decline in renal function, only 3 needed renal dialysis (range of 18 to 36 months post treatment; Orange field). The untreated historical control Stage 4 group (5 patients) had a more drastic decline in renal function, requiring dialysis (eGFR <15 ML/minute) between 4-24 months (mean - 17 months) after diagnosis (Gray field) (for colour figure refer to online version).SVF-treated patients with initial eGFRs <30 continued to deteriorate, losing 29.2% and 45.3% of renal function at 36 months for stages 4 and 5, respectively. Two of the stage 4 CKDu patients became candidates for dialysis by 18 months and a third stage 4 patient became a candidate for dialysis by 36 months. For the stage 5 SVF-treated CKDu patients, all became candidates for dialysis by 12 months. The historical cohort with 6 stage 4 CKDu patients, who started with a mean eGFR of 24, declined to an eGFR of 15, becoming candidates for dialysis between 4 and 24 months. The SVF-treated stage 4 patients appeared to be delayed in needing dialysis compared with the historical stage 4 cohort (